TABLE 2.

Primers used in this study

Primer	Sequencea
qRT-PCR
ACT1-F	5′-ACGGTGAAGAAGTTGCTGCTTTAGTT-3′
ACT1-R	5′-CGTCGTCACCGGCAAAA-3′
BMR1-F	5′-ACATAAATACTTTGCCCATCCAGAA-3′
BMR1-R	5′-AAGAGTTGGTTTGTAATCGGCTAAA-3′
CDR1-F	5′-ATTCTAAGATGTCGTCGCAAGATG-3′
CDR1-R	5′-AGTTCTGGCTAAATTCGTAATGTTTTC-3′
CDR2-F	5′-TAGTCCATTCAACGGCAACATT-3′
CDR2-R	5′-CACCCAGTATTTGGCATTGAAA-3′
CFL4-F	5′-GCAATGGTTGACAGGTTGGAA-3′
CFL4-R	5′-GCAATGTGACGATGATAAGTGACAA-3′
ERG11-F	5′-CCCCTATTAATTTTGTTTTCCCTAATTTAC-3′
ERG11-R	5′-CACGTTCTCTTCTCAGTTTAATTTCTTTC-3′
FET3-F	5′-GCCGGTGTCTTAGGTTTAGCC-3′
FET3-R	5′-CTAGCAACTCTTTCTTCAACATCGG-3′
FRP1-F	5′-CTTCCAATACCATCCATTCACGAT-3′
FRP1-R	5′-ATCTCCCCACTTTCAGCAAGAC-3′
FTR1-F	5′-ATTGTTGTTTCAGTGCTTTTGGC-3′
FTR1-R	5′-GGTCGGAACTACCACCCATAGA-3′
ERG11 mutant construction
ERG11-A	5′-GGGCCCGGGTTATTTGAGAACAGCC-3′
ERG11-B	5′-ATCCGTTCTCGAGCACTAAGGGACAA-3′
ERG11-C	5′-GTAATCAATTGAGCTCTTTTAACTTT-3′
ERG11-D	5′-GATTATAGTTCCGCGGTGGTTTTACC-3′
ERG11-E	5′-TGATGGTTTTTGTCCACTGGCTCGAG-3′
ERG11 sequencing
ERG11 seq B	5′-TATTTTCACTGCTTCAAGATCT-3′
ERG11 seq C	5′-CCAAAAGGTCATTATGTTTTAG-3′
ERG11 seq E	5′-AATGAGGTTTTTCACCTAAATG-3′
ERG11 seq F	5′-CCCTTTACCGAAAACTGGAGTA-3′
T7	5′-TAATACGACTCACTATAGGG-3′
M13R	5′-CAGGAAACAGCTATGACC-3′
UPC2 mutant construction
UPC2-A	5′-GGGCCCGAGATCTTGATGTCATTAG-3′
UPC2-B	5′-CTCGAGCTATATCTTCAATGAACTG-3′
UPC2-C	5′-CCGCGGACAGGTCAATACCGCGTAG-3′
UPC2-D	5′-GAGCTCGTTCCTCTAGTATCACTCTT-3′
UPC2-E	5′-CTCGAGCACCACAGTAACGAATCAC-3′

^aUnderlining reflects the introduction of a restriction site sequence.